Captor Therapeutics (WAR:CTX) Other Current Receivables: zł2.73 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:CTX Captor Therapeutics SA WAR:CTX
39 GF Score
Price zł75.30
GF Value zł10.11
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Captor Therapeutics Other Current Receivables?

Captor Therapeutics WAR:CTX +0.53% 39 Other Current Receivables is zł2.73 Mil as of Mar. 2026. GuruFocus rates WAR:CTX with a GF Score™ of 39/100 and a GF Value™ of zł10.11 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Captor Therapeutics's Other Current Receivables for the quarter that ended in Mar. 2026 was zł2.73 Mil.

Captor Therapeutics's quarterly Other Current Receivables declined from Sep. 2025 (zł1.80 Mil) to Dec. 2025 (zł1.35 Mil) but then increased from Dec. 2025 (zł1.35 Mil) to Mar. 2026 (zł2.73 Mil).

Captor Therapeutics's annual Other Current Receivables increased from Dec. 2023 (zł6.32 Mil) to Dec. 2024 (zł35.45 Mil) but then declined from Dec. 2024 (zł35.45 Mil) to Dec. 2025 (zł1.35 Mil).

Captor Therapeutics Other Current Receivables Related Terms

Captor Therapeutics Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Captor Therapeutics's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Captor Therapeutics Other Current Receivables Chart

Captor Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only 11.64 9.45 6.32 35.45 1.35

Captor Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.87 1.66 1.80 1.35 2.73
WAR:CTX
39GF Score
Captor Therapeutics SA WAR:CTX
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Captor Therapeutics Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of zł2.73 Mil mean?
Captor Therapeutics (WAR:CTX) has a Other Current Receivables of zł2.73 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Captor Therapeutics and its competitors.
Is Captor Therapeutics' Other Current Receivables too high?
Captor Therapeutics' current Other Current Receivables is zł2.73 Mil. Overall, Captor Therapeutics has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Captor Therapeutics' Other Current Receivables compare to VRTX and REGN?
Captor Therapeutics' Other Current Receivables of zł2.73 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Captor Therapeutics and its competitors. Captor Therapeutics's current Other Current Receivables is zł2.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Captor Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Captor Therapeutics (WAR:CTX) is currently considered Significantly Overvalued. The stock's GF Value™ is zł10.11, compared to a current price of zł75.30 — trading 644.8% above its estimated fair value. The current Other Current Receivables is zł2.73 Mil. Captor Therapeutics' overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Captor Therapeutics (WAR:CTX), the current Other Current Receivables is zł2.73 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Captor Therapeutics (WAR:CTX) Overvalued in 2026?

Based on GuruFocus' analysis, Captor Therapeutics stock appears to be overvalued. The current stock price of zł75.30 is trading 644.8% above its estimated GF Value™ of zł10.11. GuruFocus considers Captor Therapeutics to be Significantly Overvalued.

Key valuation signals for WAR:CTX:

  • Other Current Receivables: zł2.73 Mil
  • GF Value™: zł10.11 vs. price of zł75.30 (644.8% above fair value)
  • GF Score™: 39/100 with 7 warning signs

No single metric tells the full story. See the WAR:CTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Captor Therapeutics Business Description

Address ul. Dunska 11, Wroclaw, POL, 54-427
Captor Therapeutics SA is a biopharmaceutical company. It is focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options.
39GF Score

Get the complete analysis for WAR:CTX

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł75.30
Price
zł10.11
GF Value